Q-omics provides the consensus-scored RPL38P3 profile across patient tissues and cancer cell-line models. RPL38P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPL38P3 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, RPL38P3 RNA expression shows 3,985 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight CESC, COAD, and OV as cancer lineages where RPL38P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL38P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL38P3 survival associations across molecular data types. RPL38P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL38P3 RNA expression–survival associations across cancer types. High RPL38P3 expression shows unfavorable associations in THCA, KIRC and DLBC, but favorable associations in CESC, HNSC and OV. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify CESC as the clearest survival context for RPL38P3 RNA expression.
This table summarizes RPL38P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL38P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL38P3 shows lower tumor expression in LIHC and higher tumor expression in COAD and LUAD. The COAD box plot shows higher RPL38P3 RNA expression in tumor versus normal tissue (log2 FC = +0.432, t-test p = .031).
This table shows molecular features associated with RPL38P3 in patient tissues and cancer cell lines. In patient samples, RPL38P3 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
